Do you want to read an article? Please log in or register.
Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis: Results From the NutriNet-Santé Cohort
Psoriasis
Related content
Acne
Association Between Adult Acne and Dietary Behaviors: Findings From the NutriNet-Santé Prospective Cohort Study
JAMA Dermatol.
Penso L, Touvier M, Deschasaux M, Szabo de Edelenyi F, Hercberg S, Ezzedine K, Sbidian E
doi: 10.1001/jamadermatol.2020.1602.
Further Publications Immunology
The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents
Inflamm Bowel Dis.
Khan N, Trivedi C, Shah Y, Patel D, Lewis J, Yang YX
doi: 10.1093/ibd/izx115.
Atopic DermatitisPsoriasisPsoriatic Arthritis
Inflammatory dietary pattern and incident psoriasis, psoriatic arthritis, and atopic dermatitis in women: a cohort study
J Am Acad Dermatol.
Bridgman AC, Qureshi A, Li T,
Tabung FK, Cho E, Drucker AM
doi: 10.1016/j.jaad.2019.02.038.
Systemic Lupus Erythematosus
IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile
Rheumatology (Oxford).
López P, Rodríguez-Carrio J, Martínez-Zapico A, Pérez-Álvarez ÁI, Benavente L, Caminal-Montero L, Suárez A
doi: 10.1093/rheumatology/
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.
Psoriasis
Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study
Br J Dermatol
Iskandar IYK, Lunt M, Thorneloe RJ, Cordingley L, Griffiths CEM, Ashcroft DM, British Association of Dermatologists Biologics, Immunomodulators Register, Psoriasis Stratification to Optimise Relevant Therapy Study Groups.
doi: 10.1111/bjd.20577
Psoriasis
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial
J Eur Acad Dermatol Venereol
Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C
doi: 10.1111/jdv.17002
Psoriasis
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Br J Dermatol.
Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group
doi: 10.1111/bjd.17036.
Psoriasis
Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study
J Eur Acad Dermatol Venereol.
Richard MA, Lacour JP, Konstantinou MP, Ruer-Mulard M, Joly P, Aractingi S, Auquier P, Pelvet B, Augustin ML, Mahé E, Chalmers RJG
doi: 10.1111/jdv.16893.